Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.
It has been postulated that the use of highly active antiretroviral therapy (HAART) would reduce the occurrence of human immunodeficiency virus (HIV)-associated weight loss and wasting. To test this assumption, we evaluated, by means of longitudinal analysis, a prospective cohort of 469 HIV-infected individuals enrolled in a study of the impact of HIV on nutrition. Overall, 156 individuals in the cohort (33.5%) met at least 1 of these definitions of wasting. Furthermore, 58% of the cohort (289 patients) lost >1.5 kg of weight in a 6-month period between any 2 study visits. More than 50% of the cohort was receiving HAART at the time that they met 1 of the definitions of wasting; with regard to the occurrence of wasting; no differences were related to therapy.
Wanke
C A
CA
Tufts School of Medicine, Boston, MA 02111, USA. christine.wanke@tufts.edu
Silva
M
M
Knox
T A
TA
Forrester
J
J
Speigelman
D
D
Gorbach
S L
SL
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D019247:HIV Wasting Syndrome / Q000209:etiology*; D006801:Humans; D008297:Male; D015431:Weight Loss
D019380:Anti-HIV Agents